Edesa Biotech, Inc. · NASDAQ:EDSA

Edesa Biotech — Investor Presentation (September 2019)

19 slides from Edesa Biotech's investor presentation, September 2019

  1. Slide 1: Corporate Presentation

    Corporate Presentation Edesa Biotech, Inc. Nasdaq: EDSA September 2019

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such a

  3. Slide 3: Advancing Clinical-Stage Drug Candidates for Dermatological and Gastrointestinal Diseases

    Advancing Clinical-Stage Drug Candidates for Dermatological and Gastrointestinal Diseases Exploring new ways to treat Derm and GI diseases, including alternatives to topical steroids  Novel anti-inflammatory technology Topical sPLA2 inhibitor  Lead candidate targeting allergic contact dermatitis (

  4. Slide 4: Novel Approaches to Chronic Conditions

    Novel Approaches to Chronic Conditions Treating Inflammation without the Safety Concerns of Current Therapies  Inhibiting the Inflammation Cascade  sPLA2 inhibitors are designed to inhibit the inflammatory process at its inception  Exerts its anti-inflammatory activity upstream of currently appro

  5. Slide 5: Development Pipeline

    Development Pipeline Advancing and Expanding Our Growth Opportunities Drug Candidates Indications Pre-Clinical Phase 1 Phase 2 Phase 3 Allergic Contact EB01 sPLA2 Inhibitor Q3 2019: Target 1st Patient Dermatitis EB02 sPLA2 Inhibitor Hemorrhoids CTA Approved Q3 2019 Label sPLA2 Inhibitor Multiple Pen

  6. Slide 6: Allergic Contact Dermatitis

    Allergic Contact Dermatitis Disease State and Current Treatments Allergic Contact Dermatitis (ACD) is a Type IV hypersensitivity reaction Current Limited Treatment Approaches for ACD Safety Issues Often Result in Discontinuation of Treatment  Immune system sensitized with initial contact with aller

  7. Slide 7: Contact Dermatitis

    Contact Dermatitis One of the most prevalent skin conditions in U.S. Claims-Based Prevalence of Skin Disease in the US 9.0%  Contact dermatitis is a leading 8.0% occupational illness affecting 13.2 7.0% million people in U.S. at a cost of ~$2 6.0% billion annually 5.0% 4.0%  ACD represents a subma

  8. Slide 8: EB01 Efficacy in Humans Established

    EB01 Efficacy in Humans Established Phase 2 Study Demonstrated Efficacy & Safety in ACD Patients Mean Percent Improvement from Baseline in Total CDSI Score Phase 2 Efficacy Study of EB01 60 55.73% For the treatment of allergic contact dermatitis — 30 Patients Bilateral Design — 50 48.62%  Efficacy:

  9. Slide 9: Phase 2 Efficacy Study – Breakdown by Component

    Phase 2 Efficacy Study – Breakdown by Component EB01 Addressed All Aspects of CDSI Composite Score Percent Reduction in Symptoms from Baseline to Day 21* P Value = <0.001 81% P Value = <0.001 63% P Value = <0.001 P Value = <0.001 P Value = <0.001 48% 47% 46% 45% 25% 20% 20% 15% Scaling Redness Pruri

  10. Slide 10: EB01 Market Survey

    EB01 Market Survey Physicians Most Impressed with Non-Steroidal Method of Action Physician-Perceived Strengths of EB01  Key opinion leaders expressed a high desire for additional treatment options for ACD Novel anti-inflammatory product (MoA) 41%  Especially for lesions are located on face Safety

  11. Slide 11: EB01 Phase 2b Study Plan

    EB01 Phase 2b Study Plan Adaptive Design up to 166 Patients Patients with ACD EB01 2.0% (n=23) Primary Efficacy Endpoint Part A Mean Percent Change from Baseline in N=~46 Subjects Randomized (1:1) Vehicle (n=23) Contact Dermatitis Severity Index (CDSI) at Day 29 Protocol  EB01 evaluated a randomize

  12. Slide 12: Other Growth Opportunities

    Other Growth Opportunities Areas of Interest Additional Dermatological Indications Gastrointestinal Indications Additional Dermatological Indications  Platforms  Platform  Platforms  sPLA2 Inhibitor  sPLA2 Inhibitor  Under discussion  Development Status  Product Candidate  Development Statu

  13. Slide 13: Upcoming Milestones and Strategic Objectives

    Upcoming Milestones and Strategic Objectives  Strategic Transaction  Expand indications for lead asset  Reverse acquisition  EB02 study approval – CTA  Nasdaq listing  EB02 proof of concept study  Advance lead product candidate (EB01)  IND approval of EB01  Develop new markets  FDA “Safe t

  14. Slide 14: Cash Position

    Cash Position Historical Overview and Future Outlook  Balance sheet Selected Financials As of June 30, 2019  No long-term debt  Capital available for current Phase 2 Cash & Cash Equiv. $6.4 M clinical programs Total Assets $7.2 M Working Capital $6.1 M  Flexibility Debt $0.0 M  Adaptive study d

  15. Slide 15: Capitalization Table

    Capitalization Table As of August 14, 2019 Weighted Average Description Shares Exercise Price Common Shares 7,504,468 Options Outstanding1 $4.38 321,854 Warrants $11.19 48,914 Fully Diluted Shares 7,875,236 1 2017 Incentive Compensation Plan as of June 30, 2019 15

  16. Slide 16: Support from Current Shareholders

    Support from Current Shareholders Simplified Beneficial Ownership Table as of August 14, 2019 Percent Shares Percent Early Series Financing Holders Shares Share Options Outstanding Fully Diluted from Life Science Specialists Directors and Officers Pardeep Nijhawan 2,868,175 38.2% 49,110 37.0% Lorin

  17. Slide 17: Experienced Leadership Team

    Experienced Leadership Team Pharmaceutical Pipelines, Corporate Development & Strategic Transactions Senior Management Team Edesa Board of Directors Par Nijhawan, MD, FRCPC, AGAF • Board-certified gastroenterologist and Sean MacDonald CEO and Board Director hepatologist • Successful track record of

  18. Slide 18: Edesa Biotech Highlights

    Edesa Biotech Highlights  Novel technology  Inflammation inhibitor – beyond steroids  Positive evidence from two previous clinical studies  Targeting patient populations with unmet medical needs  Starting with chronic allergic contact dermatitis  Working capital flexibility  Current clinical

  19. Slide 19: Company Contacts

    Company Contacts Par Nijhawan Chief Executive Officer Michael Brooks President Gary Koppenjan Investor Relations Edesa Biotech, Inc. 100 Spy Court Markham, Ontario L3R 5H6 +1 (905) 475-1234 [email protected] www.EdesaBiotech.com

Edesa Biotech — Investor Presentation (September 2019) on 6ix